Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes.
OBJECTIVE
To assess whether there is a relationship between the effectiveness of alendronate treatment in postmenopausal women with osteoporosis and BsmI vitamin D receptor (VDR) genotypes.


METHODS
Prospective baseline-controlled clinical trial.


METHODS
Sixty-eight Italian osteoporotic women were enrolled and treated with alendronate at a dose of 10 mg/day for 12 months.


METHODS
At entry and after treatment, lumbar bone mineral density (BMD) and serum osteocalcin (OC) and urinary deoxypyridinoline/creatinine ratio (DPD-Cr) levels were evaluated. DNA was extracted from blood and analysed for the BsmI polymorphism of the VDR gene.


RESULTS
The mean percentage (% +/- SD) change from baseline in lumbar BMD was significantly higher (P < 0.01) in bb than in BB BsmI VDR genotypes (7.92 +/- 4.31 vs. 3.40 +/- 1.81). No significant difference in lumbar BMD was observed in Bb VDR patients (6.01 +/- 3.89) in comparison with other groups. The mean percentage of change in serum OC and urinary DPD-Cr levels was significantly (P < 0.01) lower in individuals with bb than in those with BB BsmI VDR genotypes (-14.34 +/- 2.87 vs.-10.39 +/- 1.43 and -9.61 +/- 5.56 vs.-4.61 +/- 2.31). No significant difference in serum OC and urinary DPD-Cr levels was observed in Bb VDR patients (-12.31 +/- 2.11 and -6.52 +/- 2.65) in comparison with other groups.


CONCLUSIONS
The different BsmI vitamin D receptor genotypes modify the pharmacological response to alendronate treatment in postmenopausal women with osteoporosis.
Palomba
Stefano
S
University of Catanzaro, Catanzaro, Italy. stefanopalomba@tin.it
Numis
Fabio Giuliano
FG
Mossetti
Giuseppe
G
Rendina
Domenico
D
Vuotto
Pietro
P
Russo
Tiziana
T
Zullo
Fulvio
F
Nappi
Carmine
C
Nunziata
Vincenzo
V
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D018167:Receptors, Calcitriol / Q000235:genetics*; D016896:Treatment Outcome
D000596:Amino Acids; D015415:Biomarkers; D018167:Receptors, Calcitriol; D015675:Osteocalcin; C036020:deoxypyridinoline; D003404:Creatinine; D019386:Alendronate